FDA’s draft guidance on AI/ML has startups on high alert
FDA, tıbbi yazılımlarda yapay zeka ve makine öğrenmesi kullanımı için taslak rehberlik yayınladı. Dokuman, AI destekli tıbbi yazılımların pazar öncesi uygulamaları ve yaşam döngüsü yönetimi için beklentileri ortaya koyuyor.
The US Food and Drug Administration (FDA) has issued draft guidance concerning the use of artificial intelligence and machine learning in medical devices. This new document, released on January 7, 2025, details the agency's expectations for both the initial approval process and ongoing management of AI-powered medical software. The guidance aims to provide a framework for ensuring the safety and effectiveness of these rapidly evolving technologies within the healthcare sector. Startups developing AI-enabled medical devices are reportedly on high alert following the release of these proposed regulations.
This guidance is significant as it establishes regulatory expectations for a rapidly growing field, potentially impacting the development and deployment of innovative medical technologies.
📌 Kaynak
Bu özet artificialintelligence kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →